ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul… By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Benzinga · Sep 12, 2022
ATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22… By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Benzinga · Jul 8, 2022
BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies… By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Benzinga · May 7, 2022
MNOV: Genzyme Patent Litigation Could Lead to Significant Payout… By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Benzinga · Apr 11, 2022
NOVN: A Banner Year for Novan - 2021 Results By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Benzinga · Mar 7, 2022
BVXV: Building a Pipeline of VHH Antibody Drug Candidates… By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Benzinga · Feb 10, 2022